Switch to:
Also traded in: France, Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.51
IPSEY's Cash-to-Debt is ranked lower than
71% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. IPSEY: 0.51 )
Ranked among companies with meaningful Cash-to-Debt only.
IPSEY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.51  Med: 9.37 Max: No Debt
Current: 0.51
Equity-to-Asset 0.47
IPSEY's Equity-to-Asset is ranked lower than
72% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. IPSEY: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
IPSEY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.62 Max: 0.64
Current: 0.47
0.47
0.64
Debt-to-Equity 0.30
IPSEY's Debt-to-Equity is ranked higher than
50% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. IPSEY: 0.30 )
Ranked among companies with meaningful Debt-to-Equity only.
IPSEY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.02 Max: 0.3
Current: 0.3
0
0.3
Debt-to-EBITDA 1.09
IPSEY's Debt-to-EBITDA is ranked higher than
63% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. IPSEY: 1.09 )
Ranked among companies with meaningful Debt-to-EBITDA only.
IPSEY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02  Med: 0.06 Max: 1.09
Current: 1.09
0.02
1.09
Interest Coverage 38.80
IPSEY's Interest Coverage is ranked lower than
58% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. IPSEY: 38.80 )
Ranked among companies with meaningful Interest Coverage only.
IPSEY' s Interest Coverage Range Over the Past 10 Years
Min: 23.39  Med: 58.38 Max: 203.33
Current: 38.8
23.39
203.33
Piotroski F-Score: 7
Altman Z-Score: 6.83
Beneish M-Score: -2.71
WACC vs ROIC
4.64%
16.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 16.71
IPSEY's Operating Margin % is ranked higher than
75% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. IPSEY: 16.71 )
Ranked among companies with meaningful Operating Margin % only.
IPSEY' s Operating Margin % Range Over the Past 10 Years
Min: 6  Med: 16.24 Max: 21.02
Current: 16.71
6
21.02
Net Margin % 11.93
IPSEY's Net Margin % is ranked higher than
70% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. IPSEY: 11.93 )
Ranked among companies with meaningful Net Margin % only.
IPSEY' s Net Margin % Range Over the Past 10 Years
Min: -2.19  Med: 12.2 Max: 15.2
Current: 11.93
-2.19
15.2
ROE % 16.36
IPSEY's ROE % is ranked higher than
78% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. IPSEY: 16.36 )
Ranked among companies with meaningful ROE % only.
IPSEY' s ROE % Range Over the Past 10 Years
Min: -2.93  Med: 16.33 Max: 19.51
Current: 16.36
-2.93
19.51
ROA % 8.59
IPSEY's ROA % is ranked higher than
73% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. IPSEY: 8.59 )
Ranked among companies with meaningful ROA % only.
IPSEY' s ROA % Range Over the Past 10 Years
Min: -1.75  Med: 9.88 Max: 11.91
Current: 8.59
-1.75
11.91
ROC (Joel Greenblatt) % 66.50
IPSEY's ROC (Joel Greenblatt) % is ranked higher than
91% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. IPSEY: 66.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IPSEY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 18.22  Med: 53.87 Max: 73.38
Current: 66.5
18.22
73.38
3-Year Revenue Growth Rate 9.50
IPSEY's 3-Year Revenue Growth Rate is ranked higher than
64% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IPSEY: 9.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IPSEY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.45 Max: 9.6
Current: 9.5
0
9.6
3-Year EBITDA Growth Rate 13.40
IPSEY's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. IPSEY: 13.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IPSEY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.05 Max: 21.8
Current: 13.4
0
21.8
3-Year EPS without NRI Growth Rate 17.10
IPSEY's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. IPSEY: 17.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IPSEY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.55 Max: 28.7
Current: 17.1
0
28.7
GuruFocus has detected 5 Warning Signs with Ipsen SA IPSEY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IPSEY's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IPSEY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OCSE:LUN, JSE:APN, SHSE:600196, NYSE:PRGO, TSE:4508, SZSE:000538, BOM:532321, HKSE:03320, XSWX:VIFN, TSE:4523, SZSE:000963, SHSE:600518, SHSE:603858, BOM:500257, SHSE:600085, BSP:HYPE3, OHEL:ORNBV, SZSE:300122, SZSE:000423, NSE:AUROPHARMA » details
Traded in other countries:IPNNV.France, I7G.Germany, 0MH6.UK,
Headquarter Location:France
Ipsen SA is a pharmaceutical company. The company mainly develops and manufactures products to serve the oncology, endocrinology, neurosciences, and primary care areas mainly across the European markets.

Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: specialty care and primary care. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focuses on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Top Ranked Articles about Ipsen SA

Roger Edgley Comments on Ipsen SA Guru stock highlight
Ipsen S.A. (XPAR:IPN) (France) was the Fund’s top contributor in the quarter. Ipsen is a pharmaceutical company with 75% of sales generated from specialty drugs. In the quarter, Ipsen announced that it would acquire the rights to Merrimack Pharmaceuticals’†† pancreatic cancer treatment. In our view, this acquisition would expand Ipsen’s oncology assets, bolster its geographic reach and provide significant growth potential. Read more...

Ratios

vs
industry
vs
history
PE Ratio 43.67
IPSEY's PE Ratio is ranked lower than
73% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.41 vs. IPSEY: 43.67 )
Ranked among companies with meaningful PE Ratio only.
IPSEY' s PE Ratio Range Over the Past 10 Years
Min: 12.7  Med: 22.05 Max: 2433
Current: 43.67
12.7
2433
Forward PE Ratio 24.75
IPSEY's Forward PE Ratio is ranked lower than
66% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. IPSEY: 24.75 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 44.01
IPSEY's PE Ratio without NRI is ranked lower than
72% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.56 vs. IPSEY: 44.01 )
Ranked among companies with meaningful PE Ratio without NRI only.
IPSEY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.77  Med: 22.09 Max: 45.9
Current: 44.01
12.77
45.9
Price-to-Owner-Earnings 60.40
IPSEY's Price-to-Owner-Earnings is ranked lower than
71% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. IPSEY: 60.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IPSEY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.51  Med: 29.33 Max: 65.64
Current: 60.4
10.51
65.64
PB Ratio 6.80
IPSEY's PB Ratio is ranked lower than
83% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. IPSEY: 6.80 )
Ranked among companies with meaningful PB Ratio only.
IPSEY' s PB Ratio Range Over the Past 10 Years
Min: 1.53  Med: 3.16 Max: 7.6
Current: 6.8
1.53
7.6
PS Ratio 5.71
IPSEY's PS Ratio is ranked lower than
69% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. IPSEY: 5.71 )
Ranked among companies with meaningful PS Ratio only.
IPSEY' s PS Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.64 Max: 6.19
Current: 5.71
1.26
6.19
Price-to-Operating-Cash-Flow 29.99
IPSEY's Price-to-Operating-Cash-Flow is ranked lower than
76% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. IPSEY: 29.99 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IPSEY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.61  Med: 14.24 Max: 32.58
Current: 29.99
6.61
32.58
EV-to-EBIT 32.52
IPSEY's EV-to-EBIT is ranked lower than
74% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. IPSEY: 32.52 )
Ranked among companies with meaningful EV-to-EBIT only.
IPSEY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 16.1 Max: 33.8
Current: 32.52
8.7
33.8
EV-to-EBITDA 25.17
IPSEY's EV-to-EBITDA is ranked lower than
71% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. IPSEY: 25.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
IPSEY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 11.9 Max: 29.9
Current: 25.17
7.3
29.9
EV-to-Revenue 5.30
IPSEY's EV-to-Revenue is ranked lower than
66% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. IPSEY: 5.30 )
Ranked among companies with meaningful EV-to-Revenue only.
IPSEY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 2.5 Max: 6.1
Current: 5.3
1.2
6.1
PEG Ratio 2.40
IPSEY's PEG Ratio is ranked lower than
58% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.89 vs. IPSEY: 2.40 )
Ranked among companies with meaningful PEG Ratio only.
IPSEY' s PEG Ratio Range Over the Past 10 Years
Min: 1.28  Med: 3.24 Max: 6.03
Current: 2.4
1.28
6.03
Shiller PE Ratio 72.41
IPSEY's Shiller PE Ratio is ranked lower than
75% of the 204 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.18 vs. IPSEY: 72.41 )
Ranked among companies with meaningful Shiller PE Ratio only.
IPSEY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 28.87  Med: 40.01 Max: 78.81
Current: 72.41
28.87
78.81
Current Ratio 1.00
IPSEY's Current Ratio is ranked lower than
90% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. IPSEY: 1.00 )
Ranked among companies with meaningful Current Ratio only.
IPSEY' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.8 Max: 2.33
Current: 1
1
2.33
Quick Ratio 0.84
IPSEY's Quick Ratio is ranked lower than
84% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. IPSEY: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
IPSEY' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.52 Max: 2.03
Current: 0.84
0.84
2.03
Days Inventory 123.93
IPSEY's Days Inventory is ranked lower than
52% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. IPSEY: 123.93 )
Ranked among companies with meaningful Days Inventory only.
IPSEY' s Days Inventory Range Over the Past 10 Years
Min: 114  Med: 159.26 Max: 176.3
Current: 123.93
114
176.3
Days Sales Outstanding 78.42
IPSEY's Days Sales Outstanding is ranked lower than
54% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. IPSEY: 78.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPSEY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.7  Med: 71.07 Max: 78.42
Current: 78.42
66.7
78.42
Days Payable 259.62
IPSEY's Days Payable is ranked higher than
93% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. IPSEY: 259.62 )
Ranked among companies with meaningful Days Payable only.
IPSEY' s Days Payable Range Over the Past 10 Years
Min: 172.18  Med: 191.1 Max: 259.62
Current: 259.62
172.18
259.62

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate 2.00
IPSEY's 3-Year Dividend Growth Rate is ranked lower than
62% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. IPSEY: 2.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
IPSEY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.1 Max: 7.7
Current: 2
0
7.7
5-Year Yield-on-Cost % 0.78
IPSEY's 5-Year Yield-on-Cost % is ranked lower than
81% of the 849 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. IPSEY: 0.78 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
IPSEY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.73  Med: 2.09 Max: 4.67
Current: 0.78
0.73
4.67
3-Year Average Share Buyback Ratio 0.20
IPSEY's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. IPSEY: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPSEY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1  Med: 0.4 Max: 0
Current: 0.2
-0.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 93.97
IPSEY's Price-to-Tangible-Book is ranked lower than
99% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. IPSEY: 93.97 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IPSEY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.69  Med: 5.8 Max: 96.5
Current: 93.97
2.69
96.5
Price-to-Intrinsic-Value-Projected-FCF 4.22
IPSEY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. IPSEY: 4.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IPSEY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 1.54 Max: 4.23
Current: 4.22
0
4.23
Price-to-Median-PS-Value 2.16
IPSEY's Price-to-Median-PS-Value is ranked lower than
99.99% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. IPSEY: 2.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IPSEY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.01 Max: 2.16
Current: 2.16
0
2.16
Price-to-Peter-Lynch-Fair-Value 2.40
IPSEY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. IPSEY: 2.40 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
IPSEY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.63 Max: 3.27
Current: 2.4
0
3.27
Price-to-Graham-Number 13.48
IPSEY's Price-to-Graham-Number is ranked lower than
98% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.97 vs. IPSEY: 13.48 )
Ranked among companies with meaningful Price-to-Graham-Number only.
IPSEY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.53  Med: 2.28 Max: 14
Current: 13.48
1.53
14
Earnings Yield (Greenblatt) % 3.08
IPSEY's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. IPSEY: 3.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IPSEY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3  Med: 6.2 Max: 11.5
Current: 3.08
3
11.5
Forward Rate of Return (Yacktman) % 18.52
IPSEY's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. IPSEY: 18.52 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IPSEY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.3  Med: 4.6 Max: 19.3
Current: 18.52
-5.3
19.3

More Statistics

Revenue (TTM) (Mil) $2,001.47
EPS (TTM) $ 0.72
Beta0.69
Short Percentage of Float0.00%
52-Week Range $16.24 - 35.86
Shares Outstanding (Mil)329.62 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,383 2,717 3,034
EPS ($) 1.01 1.37 1.70
EPS without NRI ($) 1.01 1.37 1.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.40 0.54 0.68

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}